Clavis Pharma

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Clavis Pharma sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).

5 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Clavis Pharma: 5 sponsored US clinical trials, none currently recruiting.

Clavis Pharma sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 1 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia (AML), with 1 trials.

Upper-quartile sponsor footprint

Clavis Pharma sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

5 total, page 1 of 1

COMPLETED Phase 3

Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)

NCT01147939
COMPLETED Phase 2

A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia

NCT01035502
COMPLETED Phase 2

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

NCT00498836
COMPLETED Phase 1

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

NCT00405743
COMPLETED Phase 2

Clinical Study of Previously Untreated Patients With Malignant Melanoma

NCT00232726

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3
Phase 3 1

Therapeutic Areas

Acute Myeloid Leukemia (AML) 1

How the Clavis Pharma early-phase archive is shaped

5 indexed studies, none listed as recruiting (0% open); 5 completed (100%).

Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).

Top condition: Acute Myeloid Leukemia (AML) (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Clavis Pharma: archived-pipeline peers nationwide

Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Clavis Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20%25% Total trials Recruiting share Clavis Pharma4YouandMeAbbott Rapid DxAccess Business GroupAcera Surgical10xBio22nd Century Group23andMe3-C Institute for Social Development
Clavis Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Clavis Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 5 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Clavis Pharma page

5 registered trials is a research-attention snapshot, not an endorsement of Clavis Pharma or any single study.

  • None of Clavis Pharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Acute Myeloid Leukemia (AML) is the condition Clavis Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia (AML) trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Clavis Pharma pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.